SkinBioTherapeutics has begun the final phases of its human study of SkinBiotix, to ensure that the original technology retains the same beneficial property to improve skin barrier health when in a cream formulation.
The company said Tuesday that the first of its 120 volunteers commenced testing last week. Provisional results for some of the volunteers are expected to be available for analysis at the end of December with the full read out on all 120 volunteers expected during Q1 2019.
SkinBioTherapeutics said the results of this final phase will complete the data pack to share with potential global partners interested in commercialising the SkinBiotix technology in the cosmetic skin care market.
Dr Cath O’Neill, CEO of SkinBioTherapeutics, said that SkinBiotix can be manufactured to a commercially relevant scale, freeze dried for extended shelf life and has been formulated into a skin cream which has shown no significant safety or irritancy effects in a human study. “These milestones, both individually and collectively, have reduced development risk, changed the risk reward ratio and are intended to increase interest from potential global partners,” said Dr. O’Neill.
“The final phase of the recently commenced human studies will be used to confirm product effectiveness, allowing us to complete the data pack to share with potential global partners who may be interested in commercialising the SkinBiotix technology in the cosmetic skin care market.”